- E-mail : info_medicalmarketing@jindunmedical.com
- Phone : +86 21 64057580
- Address : Shanghai China
Prasugrel, although good, is a difficult substitute for clopidogrel in elderly patients with coronary artery disease
5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]- 5,6,7,7a-tetrahydrothieno[3,2-c]pyridin-2 (4h)-one is used as the intermediate of Prasugrel .
CZYTAJ WIĘCEJReducing GI damage and replacing aspirin with clopidogrel, what to look for
D-(+)-Methyl-alpha-(2-thienylethamino)(2-chlorophenyl)acetate hydrochloride is used as the intermediate of Clopidogrel .
CZYTAJ WIĘCEJNewly approved diabetes treatment drugs on the market, no miracle drugs, beware of deception, you need to know
2-((6-chloro-3-Methyl-2,4-dioxo-3,4-dihydropyriMidin-1(2H)-yl)Methyl)-4-fluorobenzonitrile is used as the intermediate of Trelagliptin succinate .
CZYTAJ WIĘCEJOral hypoglycemic drug king "change of ownership", the birth of a new 2 billion varieties! Top 10 big reshuffle, Keren, Lep ...... heavy first generic attack
2-cyano-5-fluorine benzyl bromide is used as the intermediate of Trelagliptin succinate .
CZYTAJ WIĘCEJSodium 8 - (2-hydroxybenzamido) octanoate Salcaprozate Sodium Manufacturer
Sodium 8 - (2-hydroxybenzamido) octanoate, or SNAC for short, is a kind of absorption promoter of dicarbophosphate compounds, which is used to treat gastrointestinal diseases, espe
CZYTAJ WIĘCEJ2,6-Dichlorobenzaldehyde,CAS NO.83-38-5,export,manufacture ,supplier
2,6-dichlorobenzaldehyde is an important intermediate in the synthesis of benzoylurea insecticides. It is used to synthesize the next intermediate, 2,6-dichlorobenzaldehyde oxime,
CZYTAJ WIĘCEJDimethyl sulfoxide industry in China after 2021 driven by the dual factors of export and domestic demand rapid development
It can be used as organic solvent, reaction medium and organic synthesis intermediate.
CZYTAJ WIĘCEJHow far can anti-TB treatment with linezolid really go?
Linezolid is a new synthetic antibacterial drug of oxazolidinone developed and produced by Pharmacia&Upiohn Company (acquired by Pfizer) in the United States.
CZYTAJ WIĘCEJLatest data on ibrutinib in combination with venetoclax for first-line treatment of chronic lymphocytic leukemia released
On June 10, 2021, the American Journal of Medicine published a non-randomized phase II trial to evaluate the efficacy and safety of ibrutinib in combination with venetoclax in the
CZYTAJ WIĘCEJClinical data and adverse effects of venetoclax combined with azacitidine in the treatment of myelodysplastic syndrome
Used to synthesize BTK, PI3K and JAK-2 inhibitors, as well as pharmaceutical intermediates.
CZYTAJ WIĘCEJ